Status:
COMPLETED
An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study was an extension to study MA21573 \[NCT00750880\], which was an open label single arm study to investigate the safety, tolerability and efficacy of tocilizumab monotherapy, or combination t...
Eligibility Criteria
Inclusion
- \- patients who completed the 24-week MA21573 core study, had at least a moderate response based on EULAR definition criteria and no adverse events (AEs), serious adverse events (SAEs) or conditions that led to unacceptable risk of continued treatment.
Exclusion
- as for MA21573.
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2012
Estimated Enrollment :
934 Patients enrolled
Trial Details
Trial ID
NCT00883753
Start Date
March 1 2009
End Date
April 1 2012
Last Update
August 6 2014
Active Locations (171)
Enter a location and click search to find clinical trials sorted by distance.
1
Canberra, Australian Capital Territory, Australia, 2601
2
Coffs Harbour, New South Wales, Australia, 2450
3
Kogarah, New South Wales, Australia, 2217
4
Cairns, Queensland, Australia, 4870